Parexel Sees Surge In NME Filings, But Also Lower Chance Of Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Parexel welcomed signs of a recovery in the submissions of new molecular entities for FDA approval during 2009, floating the possibility that one major reason for the relative drought in truly new drugs entering the market in the last several years - declines in industry R&D productivity - may be easing up